Company / R&D Expense
ATOSSA THERAPEUTICS, INC. R&D Expense History
FY2013-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.4M
FY2016
5-year range
$1.1M / $2.4M
FY2013-FY2016
Trend
+112.5%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $1M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2016 with a 3-year CAGR of +6.1%.
Improved from $1M to $2M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +6.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +6.1%, indicating consistent growth.
- In FY2016, r&d expense increased 112.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $2.4M | +112.5% |
| FY2015 | $1.1M | +0.5% |
| FY2014 | $1.1M | -44.0% |
| FY2013 | $2.0M | - |
| FY2012 | - | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026